The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis

Endocrine

Volumn 45, Issue 3, 2014, Pages 462-468

  Barbaro, Daniele ^a   Incensati, Roberto Mario ^a   Materazzi, Gabriele ^b   Boni, Giuseppe ^a   Grosso, Mariano ^b   Panicucci, Erica ^b   Lapi, Paola ^a   Pasquini, Cristina ^a   Miccoli, Paolo ^b  

^a ASL 6   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

BRAF V600E mutation; Papillary thyroid cancer; Thyr 4; Thyr 5

Indexed keywords

RADIOACTIVE IODINE; B RAF KINASE; BRAF PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER CELL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CYTOLOGY; DISTANT METASTASIS; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME; CANCER GRADING; CARCINOMA; DEVICES; DNA SEQUENCE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BIOPSY, FINE-NEEDLE; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, DNA; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84897041838     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0029-5     Document Type: Article

References (45)

1. R. Siegler, D. Naishadham, A. Jemal, Cancer statistics 2012. CA Cancer J. Clin. 62(1), 10-29 (2012)
2. M.J. Schlumberger, Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 338(5), 297-306 (1998)
3. V. Popovici, E. Budinska, S. Teipar, S. Weinrich, H. Estrella, G. Hodgson, E. Van Cutsem, T. Xie, F.T. Bosman, A.D. Roth, M. Delorenzi, Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J. Clin. Oncol. 30(12), 1288-1295 (2012)
4. J. Ziai, P. Hui, BRAF mutation testig in clinical practice. Expert Rev. Mol. Diagn. 12(2), 127-138 (2012)
5. M.A. Zeiger, E.B. Schneider, BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann. Surg. Oncol. 20(1), 3-4 (2013)
6. R.P. Tufano, J. Bishop, G. Wu, Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope 122(7), 1634-1640 (2012)
7. G.M. Howell, S.E. Carty, M.J. Armstrong, S.O. Lebeau, S.P. Hodak, C. Coyne, M.T. Stang, K.L. McCoy, M.N. Nikiforova, Y.E. Nikiforov, L. Yip, Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann. Surg. Oncol. 18(13), 3566-3571 (2011)
8. G.M. Howell, M.N. Nikiforova, S.E. Carty, M.J. Armstrong, S.P. Hodak, M.T. Stang, K.L. McCoy, Y.E. Nikiforov, L. Yip, BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann. Surg. Oncol. 20(1), 47-52 (2012)
9. S.J. Kim, K.E. Lee, J.P. Myong, J.H. Park, Y.K. Jeon, H.S. Min, S.Y. Park, K.C. Jung, H. Koo do, Y.K. Youn, BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J. Surg. 36(2), 310-317 (2012)
10. W. Wang, W. Zhao, H. Wang, X. Teng, H. Wang, X. Chen, Z. Li, X. Yu, T.J. Fahey 3rd, L. Teng, Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann. Surg. Oncol. 19(1), 31-36 (2012)
11. A. Chakraborty, A. Narkar, R. Mukhopadhyaya, S. Kane, A. D'Cruz, M.G. Rajan, BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr. Pathol. 23(2), 83-93 (2012)
12. N. Kurtulmus, M. Duren, U. Ince, M. Cengiz Yakicier, O. Peker, O. Aydin, E. Altiok, S. Giray, H. Azizlerli, BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42(2), 404-410 (2012)
13. Y.L. Zhou, W. Zhang, E.L. Gao, X.X. Dai, H. Yang, X.H. Zhang, O.C. Wang, Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Asian Pac. J. Cancer Prev. 13(4), 1267-1272 (2012)
14. X. Lee, M. Gao, Y. Ji, Y. Yu, Y. Feng, Y. Li, Y. Zhang, W. Cheng, W. Zhao, Analysis of differential BRAF V600E mutational status in high aggressive papillary thyroid microcarcinoma. Ann. Surg. Oncol. 16(2), 240-245 (2009)
15. R. Elisei, D. Viola, L. Torregrossa, R. Giannini, C. Romei, C. Ugolini, E. Molinaro, L. Agate, A. Biagini, C. Lupi, L. Valerio, G. Materazzi, P. Miccoli, P. Piaggi, A. Pinchera, P. Vitti, F. Basolo, The BRAF V600 E mutation is an indipendent, poor prognostic factor fort the out come of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J. Clin. Endocrin. Metab. 97(12), 4390-4398 (2012)
16. J.Y. Joo, J.Y. Park, Y.H. Yoon, B. Choi, J.M. Kim, Y.S. Jo, M. Shong, B.S. Koo, Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J. Clin. Endocrinol. Metab. 97(11), 3996-4003 (2012)
17. C. Nucera, A. Pontecorvi, Clinical outcome, role of BRAF(V600E), andmolecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol. (Lausanne) 3, 33 (2012)
18. R.P. Tufano, G.V. Teixeira, J. Bishop, K.A. Carson, M. Xing, BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 91(5), 274-286 (2012)
19. C. Nucera, J. Lawler, R. Hodin, S. Parangi, The BRAF V600E mutation: what is really orchestrating in thyroid cancer? Oncotarget 1(8), 751-756 (2010)
20. Dutenhefner SE, Marui S, Santos AB, Lima EU, Inoue M, Neto JD, Shiang C, Fukushima J, Cernea CR, Friguglietti C 2012 BRAF, a tool in the decision to perform elective neck dissection? Thyroid Nov 27 (2012)
21. X. Li, A.B. Abdel-Mageed, E. Kandil, BRAF mutation in papillary thyroid carcinoma. Int. J. Clin. Exp. Med. 5(4), 310-315 (2012)
22. H. Pelttari, C. Schalin-Jäntti, J. Arola, E. Löyttyniemi, S. Knuutila, M.J. Välimäki, BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS 120(5), 380-386 (2012)
23. C. Eloy, J. Santos, P. Soares, M. Sobrinho-Simoes, The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch. 459(3), 265-276 (2011)
24. J.K. Nam, C.K. Jung, B.J. Song, D.J. Lim, B.J. Chae, N.S. Lee, W.C. Park, J.S. Kim, S.S. Jung, J.S. Bae, Is the BRAF (V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am. J. Surg. 203(4), 436-441 (2012)
25. D. Ahn, J.S. Park, J.H. Sohn, J.H. Kim, S.K. Park, A.N. Seo, J.Y. Park, BRAF (V600E) mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx 39(2), 198-203 (2012)
26. T.Y. Kim, W.B. Kim, J.Y. Song, Y.S. Rhee, G. Gong, Y.M. Cho, S.Y. Kim, S.C. Kim, S.J. Hong, Y.K. Shong, The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin. Endocrinol. (Oxf) 63(5), 588-593 (2005)
27. T.H. Kim, Y.J. Park, J.A. Lim, H.Y. Ahn, E.K. Lee, Y.J. Lee, K.W. Kim, S.K. Hahn, Y.K. Youn, K.H. Kim, B.Y. Cho, J. do Park, The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118(7), 1764-1773 (2012)
28. C. Li, K.C. Lee, B. Schneider, M.A. Zeiger, BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J. Clin. Endocrinol. Metab. 97(12), 4559-4570 (2012)
29. K.C. Lee, C. Li, E.B. Schneider, Y. Wang, H. Somervell, M. Krafft, C.B. Umbricht, M.A. Zeiger, Is BRAF Imutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery 152(6), 977-983 (2012)
30. Y.K. So, Y.I. Son, J.Y. Park, C.H. Baek, H.S. Jeong, M.K. Chung, Preoperative BRAF Mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol. Head Neck Surg. 145(3), 422-427 (2011)
31. A. Proietti, R. Giannini, C. Ugolini, M. Miccoli, G. Fontanini, G. Di Coscio, R. Romani, P. Berti, P. Miccoli, F. Basolo, BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. Thyroid 20(11), 1263-1270 (2010)
32. C. Romei, L. Fugazzola, E. Puxeddu, F. Frasca, D. Viola, M. Muzza, S. Moretti, L.M. Nicolosi, C. Giani, V. Cirello, N. Avenia, S. Rossi, P. Vitti, A. Pinchera, R. Elisei, Modifications in the papillary thyroid cancer gene profile over the last 15 years. J. Clin. Endocrinol. Metab. 97(9), E1758-E1765 (2012)
33. J.D. Prescott, P.M. Sadow, R.A. Hodin, L.P. Le, R.D. Gaz, G.W. Randolph, A.E. Stephen, S. Parangi, G.H. Daniels, C.C. Lubitz, BRAF (V600E) status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery 152(6), 984-990 (2012)
34. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167-1214 (2009)
35. M. Xing, A.S. Alzahrani, K.A. Carson, D. Viola, R. Elisei, B. Bendlova, L. Yip, C. Mian, F. Vianello, R.M. Tuttle, E. Robenshtok, J.A. Fagin, E. Puxeddu, L. Fugazzola, A. Czarniecka, B. Jarzab, C.J. O'Neill, Sywak, A.K. Lam, G. Riesco-Eizaguirre, P. Santisteban, H. Nakayama, R.P. Tufano, S.I. Pai, M.A. Zeiger, W.H. Westra, D.P. Clark, R. Clifton-Bligh, D. Sidransky, P.W. Ladenson, V. Sykorova, Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309 (14), 1493-1501 (2013)
36. J.C. Watkinson, The Brithish Thyroid Association guidelines for the management of thyroid cancer in adults. Nucl. Med. Commun. 25(9), 897-900 (2004)
37. A. Guerra, V. Marotta, M. Deandrea, M. Motta, P.P. Limone, A. Caleo, P. Zeppa, S. Esposito, F. Fulciniti, M. Vitale, BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Endocrine (2012). doi:10.1007/s12020-012-9843-4
38. C. Durante, E. Puxeddu, E. Ferretti, R. Morisi, S. Moretti, R. Bruno, F. Barbi, N. Avenia, A. Scipioni, A. Verrienti, E. Tosi, A. Cavaliere, A. Gulino, S. Filetti, D. Russo, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92(7), 2840-2843 (2007)
39. Pupilli C, Pinzani P, Salvianti F, Fibbi B, Rossi M, Petrone L, Perigli G, De Feo M, Vezzosi V, Pazzagli M, Orlando C, Forti G Circulating BRAFV600E in the diagnosis and follow up of differentiated papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. Jun 20 (2013)
40. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, Cho JY Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer; a subgroup analysis of 3130 cases in a single center. Thyroid Mar 17 (2013)
41. E. Puxeddu, C. Durante, N. Avenia, S. Filetti, D. Russo, Clinical implications of BRAF muttion in thyroid carcinoma. Trends Endocrinol. Metab. 19 (4), 138-145 (2008)
42. M. Xing, Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol. Cell. Endocrinol. 32(1), 86-93 (2010)
43. Wartofsky L Should patients with papillary microcarcinoma undergo radioiodine ablation? Endocrine Jul 2 (2013)
44. Kunavisarut T Diagnostic biomarkers of differentiated thyroid cancer. Endocrine May 4 (2013)
45. Guerra A, Di Stasi V, Zeppa P, Faggiano A, Marotta V, Vitale M BRAF V600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay. Endocrine Dec 1 (2013)